BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 38570490)

  • 21. Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis.
    Zubeldia-Plazaola A; Recalde-Percaz L; Moragas N; Alcaraz M; Chen X; Mancino M; Fernández-Nogueira P; Prats de Puig M; Guzman F; Noguera-Castells A; López-Plana A; Enreig E; Carbó N; Almendro V; Gascón P; Bragado P; Fuster G
    Breast Cancer Res; 2018 Jul; 20(1):65. PubMed ID: 29973218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
    Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F
    Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
    Zeng Y; Gao W; Chen X; Shen K
    Br J Cancer; 2021 Mar; 124(5):975-981. PubMed ID: 33335279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
    Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V
    Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positive enhancement integral values in dynamic contrast enhanced magnetic resonance imaging of breast carcinoma: ductal carcinoma in situ vs. invasive ductal carcinoma.
    Nadrljanski M; Maksimović R; Plešinac-Karapandžić V; Nikitović M; Marković-Vasiljković B; Milošević Z
    Eur J Radiol; 2014 Aug; 83(8):1363-7. PubMed ID: 24894697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma
    Lo PK; Zhang Y; Yao Y; Wolfson B; Yu J; Han SY; Duru N; Zhou Q
    J Biol Chem; 2017 Jul; 292(27):11466-11484. PubMed ID: 28512126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ.
    Brock EJ; Ji K; Shah S; Mattingly RR; Sloane BF
    J Mammary Gland Biol Neoplasia; 2019 Mar; 24(1):1-15. PubMed ID: 30056557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progression from ductal carcinoma in situ to invasive breast cancer: revisited.
    Cowell CF; Weigelt B; Sakr RA; Ng CK; Hicks J; King TA; Reis-Filho JS
    Mol Oncol; 2013 Oct; 7(5):859-69. PubMed ID: 23890733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus Inhibits the Progression of Ductal Carcinoma
    Chen G; Ding XF; Pressley K; Bouamar H; Wang B; Zheng G; Broome LE; Nazarullah A; Brenner AJ; Kaklamani V; Jatoi I; Sun LZ
    Clin Cancer Res; 2020 Mar; 26(6):1486-1496. PubMed ID: 31871301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management.
    Hophan SL; Odnokoz O; Liu H; Luo Y; Khan S; Gradishar W; Zhou Z; Badve S; Torres MA; Wan Y
    Endocrinology; 2022 Apr; 163(4):. PubMed ID: 35245349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An extracellular matrix stiffness-induced breast cancer cell transcriptome resembles the transition from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).
    Göransson S; Chen S; Olofsson H; Larsson O; Strömblad S
    Biochem Biophys Res Commun; 2023 Apr; 654():73-79. PubMed ID: 36893606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
    Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
    Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
    Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
    Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The molecular journey from ductal carcinoma in situ to invasive breast cancer.
    Wiechmann L; Kuerer HM
    Cancer; 2008 May; 112(10):2130-42. PubMed ID: 18383519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
    Logullo AF; Nonogaki S; Pasini FS; Osório CA; Soares FA; Brentani MM
    Oncol Rep; 2010 Feb; 23(2):313-20. PubMed ID: 20043090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
    Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
    Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.